Comparison · NCT02808871-e47fb8e0
Pirfenidone vs Placebo: Number of Participants With FVC Decline From Baseline of 10% or Greater
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Pirfenidone vs Placebo: Number of Participants With FVC Decline From Baseline of 10% or Greater. Trial comparisons, record NCT02808871-e47fb8e0. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02808871-e47fb8e0
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0794 | 0.0344 | 0.173 | wilson | |
| Risk in group 2 | 0.117 | 0.0577 | 0.222 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0373 | -0.152 | 0.0731 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.68 | 0.228 | 2.03 | log | |
| Odds ratio, group 1 over group 2 | 0.653 | 0.195 | 2.18 | log | |
| Number needed to treat, for one fewer participant with the outcome on Pirfenidone than on Placebo | 26.8 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Pirfenidone | Pirfenidone 2403 mg/d for 52 weeks | 5 | 63 | OG000 |
| Group 2 | Placebo | Placebo for 52 weeks | 7 | 60 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With FVC Decline From Baseline of 10% or Greater
- Description
- Number of participants with decline from baseline in percent predicted FVC of 10% or greater during the study period.
- Time frame
- 52 weeks
- Population
Source ClinicalTrials.gov
Trial
- Title
- Phase ll Study of Pirfenidone in Patients With RAILD (TRAIL1)
- NCT number
- NCT02808871
- Phases
- PHASE2
- Conditions
- Rheumatoid Arthritis Interstitial Lung Disease
- Interventions
- Pirfenidone, Placebo
- Lead sponsor
- Brigham and Women's Hospital
- Results first posted
- 2022-08-16
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02808871?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02808871-e47fb8e0